The Royal Marsden Hospital and The Institute of Cancer Research, London, UK

University Medical Centre Mannheim, University of Heidelberg, Germany

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Vall d’Hebron University Hospital, Barcelona, Spain

Multidisciplinary team members with an interest in the management of patients with MET ex14 skipping NSCLC

• To highlight the importance of testing for MET ex14 skipping in patients with NSCLC
• To examine recent evidence describing the efficacy and safety of tepotinib in this patient population
• To share practical insight into the management of these patients using case studies

This Industry-Sponsored Symposium is organized and sponsored by Merck Healthcare KGaA.

This program was approved by the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

In the European Economic Area (EEA), tepotinib as monotherapy is indicated for the treatment of adult patients with advanced NSCLC harbouring MET ex14 skipping alterations, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. Click here to view full Prescribing Information. For HCPs from other regions/countries, please check your locally approved Product Information.

© Merck Healthcare KGaA. Darmstadt, Germany. All rights reserved. June 2022. GL-TEP-00219.